Cargando…

Retention on Buprenorphine Is Associated with High Levels of Maximal Viral Suppression among HIV-Infected Opioid Dependent Released Prisoners

INTRODUCTION: HIV-infected prisoners lose viral suppression within the 12 weeks after release to the community. This prospective study evaluates the use of buprenorphine/naloxone (BPN/NLX) as a method to reduce relapse to opioid use and sustain viral suppression among released HIV-infected prisoners...

Descripción completa

Detalles Bibliográficos
Autores principales:	Springer, Sandra A., Qiu, Jingjun, Saber-Tehrani, Ali Shabahang, Altice, Frederick L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3365007/ https://www.ncbi.nlm.nih.gov/pubmed/22719814 http://dx.doi.org/10.1371/journal.pone.0038335

Ejemplares similares

Improved HIV and Substance Abuse Treatment Outcomes for Released HIV-Infected Prisoners: The Impact of Buprenorphine Treatment
por: Springer, Sandra Ann, et al.
Publicado: (2010)

Emergency Department Use by Released Prisoners with HIV: An Observational Longitudinal Study
por: Meyer, Jaimie P., et al.
Publicado: (2012)

Predictors of Linkage to and Retention in HIV Care Following Release from Connecticut Jails and Prisons
por: Loeliger, Kelsey B, et al.
Publicado: (2017)

Comparison of Treatment Retention of Adults With Opioid Addiction Managed With Extended-Release Buprenorphine vs Daily Sublingual Buprenorphine-Naloxone at Time of Release From Jail
por: Lee, Joshua D., et al.
Publicado: (2021)

Telemedicine Buprenorphine Initiation and Retention in Opioid Use Disorder Treatment for Medicaid Enrollees
por: Hammerslag, Lindsey R., et al.
Publicado: (2023)

Managing opioid withdrawal precipitated by buprenorphine with buprenorphine
por: Oakley, Bridget, et al.
Publicado: (2021)

OUD Care Service Improvement with Prolonged-release Buprenorphine in Prisons: Cost Estimation Analysis
por: Wright, Nat, et al.
Publicado: (2020)

A comparison of psychiatric diagnoses among HIV-infected prisoners receiving combination antiretroviral therapy and transitioning to the community
por: Di Paola, Angela, et al.
Publicado: (2014)

Correlates of HIV infection and being unaware of HIV status among soon-to-be-released Ukrainian prisoners
por: Azbel, Lyuba, et al.
Publicado: (2014)

Economic Evaluation of Extended-Release Buprenorphine for Persons With Opioid Use Disorder
por: Flam-Ross, Juliet M., et al.
Publicado: (2023)

Prospective study of retention in opioid agonist treatment and contact with emergency healthcare following release from prisons in Victoria, Australia
por: Curtis, Michael, et al.
Publicado: (2023)

Impact of prerelease methadone on mortality among people with HIV and opioid use disorder after prison release: results from a randomized and participant choice open-label trial in Malaysia
por: Bazazi, Alexander R., et al.
Publicado: (2022)

1025. Integrating buprenorphine into an urban HIV primary care practice: Outcomes on viral load suppression and opioid use
por: Fabricant, Scott, et al.
Publicado: (2020)

Comparison of Buprenorphine and Buprenorphine/naloxone in Detoxification of Opioid-dependent Men
por: Ziaaddini, Hassan, et al.
Publicado: (2018)

Latent tuberculosis infection in a Malaysian prison: implications for a comprehensive integrated control program in prisons
por: Al-Darraji, Haider Abdulrazzaq Abed, et al.
Publicado: (2014)

Predictors of mortality within prison and after release among persons living with HIV in Indonesia
por: Culbert, Gabriel J, et al.
Publicado: (2017)

Successful Treatment of Opioid Dependence with Flexible Doses of Injectable Prolonged Release Buprenorphine
por: D'Agnone, Oscar
Publicado: (2019)

Buprenorphine treatment retention and comorbidities among patients with opioid use disorder in a primary care setting
por: Sweeney, Mary M., et al.
Publicado: (2022)

Impact of opioid substitution therapy for Scotland's prisoners on drug‐related deaths soon after prisoner release
por: Bird, Sheila M., et al.
Publicado: (2015)

Advances in the delivery of buprenorphine for opioid dependence
por: Rosenthal, Richard N, et al.
Publicado: (2017)

Role of Buprenorphine in an Adolescent with Opioid Abuse
por: Weesner, Elizabeth, et al.
Publicado: (2022)

Buprenorphine‐naloxone, buprenorphine, and methadone throughout pregnancy in maternal opioid use disorder
por: Kanervo, Minna M., et al.
Publicado: (2022)

Correlates of Nine-Month Retention following Interim Buprenorphine-Naloxone Treatment in Opioid Dependence: A Pilot Study
por: Håkansson, A., et al.
Publicado: (2016)

Use of and Retention on Video, Telephone, and In-Person Buprenorphine Treatment for Opioid Use Disorder During the COVID-19 Pandemic
por: Frost, Madeline C., et al.
Publicado: (2022)

Trends in Buprenorphine Use in US Jails and Prisons From 2016 to 2021
por: Thakrar, Ashish P., et al.
Publicado: (2021)

Detection of methadone and buprenorphine in urine samples from inmates of German prisons
por: Franchetti, Giorgia, et al.
Publicado: (2023)

Perceptions of extended‐release buprenorphine injections for opioid use disorder among people who regularly use opioids in Australia
por: Larance, Briony, et al.
Publicado: (2020)

A Delta-Opioid Receptor Gene Polymorphism Moderates the Therapeutic Response to Extended-Release Buprenorphine in Opioid Use Disorder
por: Kranzler, Henry R, et al.
Publicado: (2020)

Increased Treatment Engagement and Adherence: Flexible Management with Prolonged-Release Buprenorphine in Treatment of Opioid Dependence
por: Hard, Bernadette
Publicado: (2021)

Systematic Review of the Safety and Tolerability of Injectable Prolonged-Release Buprenorphine (Buvidal) in Adults With Opioid Dependence
por: Williams, Laura, et al.
Publicado: (2023)

Timing of hepatitis C treatment initiation and retention in office-based opioid treatment with buprenorphine: a retrospective cohort study
por: Geist, Mary L., et al.
Publicado: (2023)

Treatment of opioid dependence with buprenorphine: current update
por: Soyka, Michael
Publicado: (2017)

The Pharmacology of Buprenorphine Microinduction for Opioid Use Disorder
por: De Aquino, Joao P., et al.
Publicado: (2021)

Examining the benefit of a higher maintenance dose of extended-release buprenorphine in opioid-injecting participants treated for opioid use disorder
por: Greenwald, Mark K., et al.
Publicado: (2023)

Management of Opioid Addiction With Opioid Substitution Treatments: Beyond Methadone and Buprenorphine
por: Noble, Florence, et al.
Publicado: (2019)

Patients Maintained on Buprenorphine for Opioid Use Disorder Should Continue Buprenorphine Through the Perioperative Period
por: Lembke, Anna, et al.
Publicado: (2019)

Evaluating buprenorphine prescribing and opioid-related health outcomes following the expansion the buprenorphine waiver program
por: Rowe, Christopher L., et al.
Publicado: (2022)

Association between Participation in Counseling and Retention in a Buprenorphine-Assisted Treatment Program for People Experiencing Homelessness with Opioid Use Disorder
por: Berry, Amanda R. W., et al.
Publicado: (2021)

Retention in HIV care during the 3 years following release from incarceration: A cohort study
por: Loeliger, Kelsey B., et al.
Publicado: (2018)

1901. High Prevalence of Latent Tuberculosis Infection in a Malaysian Prison
por: Zhang, Lu, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_hj2b8271engi4uf1l94dqfg9ec